Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
Hepatitis C is a major health problem. In recent years, the treatment of choice is alpha-interferon in combination with ribavirin. For patients with failure of this treatment the therapy with consensus or pegylated interferons, in monotherapy or in combination with ribavirin, present other possibilities. We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31)
Husa
P
P
Department of Infectious Diseases, Teaching Hospital, Jihlavska 20, CZ-639 00 Brno, Czech Republic. phusa@med.muni.cz
Husova
L
L
D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C050739:interferon alfacon-1; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a